Alkermes (NASDAQ:ALKS) Given New $35.00 Price Target at Piper Sandler

Alkermes (NASDAQ:ALKS – Free Report) had its price objective decreased by Piper Sandler from $37.00 to $35.00 in a research note issued to investors on Friday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the stock. ALKS has been the subject of several other reports. UBS Group started coverage on shares of […]

Leave a Reply

Your email address will not be published.

Previous post Piper Sandler Lowers ChampionX (NASDAQ:CHX) Price Target to $38.00
Next post Initiates Coverage on OncoCyte (NASDAQ:OCX)